Loading the company profile
Public data, as of October 2026
Company profile
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. reported about 170,000 tCO₂e for 2024, and 93% of it sits in Scope 3, in the value chain beyond the company's own operations.
SBTi status
No SBTi record is linked to this company yet.
Where insetting fits
Scope 3 is 93% of the footprint, the part of the value chain that supplier emissions reductions can reach.
Peer position
Scope 3 is 93% of the footprint, close to the peer median of 94%.
Voluntary retirements
Registry records show 181 credits retired for this company.
Emissions
How the reported footprint breaks down by scope and year.
tCO₂e, GHG Protocol scopes
Source: published disclosure, FY2024
Peer benchmark
How Alnylam Pharmaceuticals, Inc. compares with its industry peers on Scope 3.
Peers: companies in the broad registry sector "Pharmaceuticals". No SBTi industry is linked yet, so treat this as a rough comparison.
CompanyScope 3 share%
- Alnylam Pharmaceuticals, Inc.This company93%
- Merck KGaA81%
Company profile
A claimed profile keeps the figures accurate and shows the company’s projects.
Claiming is free. Your team can correct data, add newer disclosures and list reduction projects from your value chain, so that customers and suppliers can co-fund them.
- 1Confirm employment at the company